We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Gilead to Pay Merck $2.5B in Record Patent Ruling Over Hep C Therapies
Gilead to Pay Merck $2.5B in Record Patent Ruling Over Hep C Therapies
Gilead will have to pay Merck $2.5 billion for infringing a patent that covers the active ingredient of its blockbuster hepatitis C drugs, Salvadi and Harvoni, in the country’s largest ever judgment for an infringement.